Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

Benralizumab reduces oral corticosteroid requirements in patients with EGPA and leads to improved patient-reported outcome measures https://bit.ly/2GI0vhf

Detalles Bibliográficos
Autores principales: Nanzer, Alexandra M., Dhariwal, Jaideep, Kavanagh, Joanne, Hearn, Andrew, Fernandes, Mariana, Thomson, Louise, Roxas, Cris, Green, Linda, D'Ancona, Grainne, Agarwal, Sangita, Kent, Brian D., Jackson, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682702/
https://www.ncbi.nlm.nih.gov/pubmed/33263051
http://dx.doi.org/10.1183/23120541.00451-2020
Descripción
Sumario:Benralizumab reduces oral corticosteroid requirements in patients with EGPA and leads to improved patient-reported outcome measures https://bit.ly/2GI0vhf

Ejemplares similares